177 related articles for article (PubMed ID: 15586308)
1. [Social psychiatry and schizophrenia--changes and perspectives].
Dettling M; Schönhoff M
Psychiatr Prax; 2004 Nov; 31 Suppl 2():S185-8. PubMed ID: 15586308
[TBL] [Abstract][Full Text] [Related]
2. [Schizophrenia as the prototypical psychiatric disorder].
Vauth R; Hohagen F; Lotz-Rambaldi W
Psychiatr Prax; 2012 May; 39(4):153-6. PubMed ID: 22562697
[No Abstract] [Full Text] [Related]
3. [For and against: a crisis of community psychiatry? Against].
Brieger P
Psychiatr Prax; 2005 Sep; 32(6):270-1. PubMed ID: 16167394
[No Abstract] [Full Text] [Related]
4. [Research in social psychiatry - addressing future challenges of health- and social systems].
Riedel-Heller SG
Neuropsychiatr; 2009; 23(4):249-52. PubMed ID: 19909696
[TBL] [Abstract][Full Text] [Related]
5. [Early rehabilitation for chronic mentally ill during inpatient stay--court decision strengthens social-psychiatric treatment approach].
Weig W
Psychiatr Prax; 2005 Sep; 32(6):267-8. PubMed ID: 16094550
[No Abstract] [Full Text] [Related]
6. [Cost assessment in a fragmented psychiatric treatment system].
Salize HJ; Rössler W; Reinhard I
Gesundheitswesen; 1996 Jul; 58(1 Suppl):10-7. PubMed ID: 8963083
[TBL] [Abstract][Full Text] [Related]
7. [Cost and benefits in social psychiatry: should one economize or develop?].
Ciompi L
Rev Med Suisse Romande; 1993 Oct; 113(10):805-13. PubMed ID: 8256065
[No Abstract] [Full Text] [Related]
8. [Cognitive remediation and cognitive assistive technologies in schizophrenia].
Sablier J; Stip E; Franck N
Encephale; 2009 Apr; 35(2):160-7. PubMed ID: 19393385
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
[TBL] [Abstract][Full Text] [Related]
11. [For and against: a crisis of community psychiatry? For].
Eikelmann B; Richter D; Reker T
Psychiatr Prax; 2005 Sep; 32(6):269-70. PubMed ID: 16094551
[No Abstract] [Full Text] [Related]
12. [Sociocultural aspects in the clinical picture and socio-occupational rehabilitation of schizophrenia].
Predescu V; Alexandrescu C
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1985; 30(2):81-104. PubMed ID: 2864730
[No Abstract] [Full Text] [Related]
13. [Schizophrenic patients' length of stay: mental health care implication and medicoeconomic consequences].
Capdevielle D; Boulenger JP; Villebrun D; Ritchie K
Encephale; 2009 Sep; 35(4):394-9. PubMed ID: 19748377
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic modelling in schizophrenia. Trap or support for decision makers?
Hansen K; Lançon C; Toumi M
Eur J Health Econ; 2006 Mar; 7(1):19-29. PubMed ID: 16528579
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacoeconomic review of the use of injectable long-acting risperidone].
Bartkó G; Fehér L
Neuropsychopharmacol Hung; 2005 Dec; 7(4):199-207. PubMed ID: 16496485
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of the prevention of relapse of schizophrenia in the longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS).
Bernardo M; Azanza JR; Rubio-Terrés C; Rejas J
Actas Esp Psiquiatr; 2007; 35(4):259-62. PubMed ID: 17592789
[TBL] [Abstract][Full Text] [Related]
17. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
18. [Qualitative research in social psychiatry--methods and applications].
Flick U
Psychiatr Prax; 1995 May; 22(3):91-6. PubMed ID: 7610207
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in Spain.
Gutierrez-Recacha P; Chisholm D; Haro JM; Salvador-Carulla L; Ayuso-Mateos JL
Acta Psychiatr Scand Suppl; 2006; (432):29-38. PubMed ID: 17087813
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.
Obradovic M; Mrhar A; Kos M
Int J Clin Pract; 2007 Dec; 61(12):1979-88. PubMed ID: 17997804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
